|
gptkbp:instanceOf
|
gptkb:drug
anticonvulsant
|
|
gptkbp:approvalYear
|
2008
|
|
gptkbp:approvedBy
|
gptkb:United_States
gptkb:FDA
|
|
gptkbp:ATCCode
|
N03AX18
|
|
gptkbp:brand
|
gptkb:Vimpat
|
|
gptkbp:CASNumber
|
175481-36-4
|
|
gptkbp:chemicalFormula
|
C13H18N2O3
|
|
gptkbp:contraindication
|
gptkb:second-_or_third-degree_AV_block
|
|
gptkbp:developedBy
|
gptkb:UCB_Pharma
|
|
gptkbp:eliminationHalfLife
|
13 hours
|
|
gptkbp:excretion
|
renal
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
lacosamide
|
|
gptkbp:interactsWith
|
other antiepileptic drugs
drugs that prolong PR interval
|
|
gptkbp:IUPACName
|
(R)-2-acetamido-N-benzyl-3-methoxypropanamide
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
enhances slow inactivation of voltage-gated sodium channels
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
250.295 g/mol
|
|
gptkbp:patentExpired
|
2022 (US)
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
less than 15%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
DB06218
174388
201164
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nausea
dizziness
fatigue
headache
diplopia
|
|
gptkbp:UNII
|
O5C6TUG9ZZ
|
|
gptkbp:usedFor
|
epilepsy
partial-onset seizures
|
|
gptkbp:bfsParent
|
gptkb:Vimpat
gptkb:Schedule_V_controlled_substance_(US)
gptkb:Schedule_V_(US_Controlled_Substances_Act)
|
|
gptkbp:bfsLayer
|
8
|